INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up.

Abstract

PURPOSE:

To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR).

METHODS:

Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection.

RESULTS:

The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coherence tomography improved statistically significantly (P < 0.0001, both comparisons). Three eyes without previous panretinal photocoagulation ("naive" eyes) and with vitreous hemorrhage did not require vitreoretinal surgery. Five (5.2%) eyes with PDR progressed to tractional retinal detachment requiring vitrectomy. No systemic adverse events were noted.

CONCLUSION:

Intravitreal bevacizumab resulted in marked regression of retinal neovascularization in patients with PDR and previous panretinal photocoagulation. Intravitreal bevacizumab in naive eyes resulted in control or regression of 42.1% of eyes without adjunctive laser or vitrectomy during 24 months of follow-up. There were no safety concerns during the 2 years of follow-up of IVB for PDR.

• Authors: J Fernando Arevalo, Andres F Lasave, Lihteh Wu, Mauricio Maia, Manuel Diaz-Llopis, Arturo A Alezzandrini, Miguel Brito, Pan-American Collaborative Retina Study Group (PACORES)
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 37 Issue 2 Pg. 334-343 (Feb 2017) ISSN: 1539-2864 [Electronic] United States
• PMID: 27429384 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Angiogenesis Inhibitors
• Bevacizumab

Topics

• Adult
• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Bevacizumab (administration & dosage)
• Diabetic Retinopathy (drug therapy, physiopathology)
• Female
• Follow-Up Studies
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Retinal Neovascularization (drug therapy, physiopathology)
• Retrospective Studies
• Tomography, Optical Coherence
• United States
• Visual Acuity
• Vitrectomy